In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals ...

After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings ...

Unexpectedly catapulted into global fame as a COVID-19 vaccine maker, BioNTech is on the verge of returning to its oncology ...

Aiming to streamline the compensation process for people claiming harm from COVID-19 vaccines, Robert F. | Aiming to ...

In a first for the neurotoxin market, Ipsen announced Thursday that its Dysport has hit the goals in two phase 3 trials for the prevention of both episodic and chronic migraines. While AbbVie’s market ...

The CARDIO-TTRansform study did not meet its primary endpoint, which centered on reducing cardiovascular deaths or recurrent ...

When launching a drug as big as semaglutide, even as a generic, the market expectations are immense, and any fumble on the ...

The comment-seeking period and probe tie back to Sanofi’s marketing for its flu shot for adults ages 60 and over, which is ...

Following a major push by the industry’s heavyweights to simplify their businesses in recent years, Tanabe Pharma is | While ...

Lundbeck’s online promotion of migraine med Vyepti has caught the attention of the FDA, with the agency inking an untitled letter that calls out the company for potentially misleading efficacy claims.

AbbVie’s Allergan Aesthetics, looking to open doors for the next generation of female leaders, welcomed a cohort of young ...

After pledging earlier this year to bolster its drug substance capabilities in Central Europe, German chemical company Evonik is turning its attention to the U.S. The company is laying out $100 ...